Studies from Hospital and Research Centre Have Provided New Data on Tuberous Sclerosis (Therapeutic effect of Topical Sirolimus on Facial Angiofibromas in Patients of Tuberous Sclerosis Complex).

A study conducted at a Hospital and Research Centre has found that topical sirolimus, an mTOR inhibitor, is an effective treatment for facial angiofibromas in patients with tuberous sclerosis complex (TSC). TSC is a rare autosomal dominant disorder, and facial angiofibromas are the most common cutaneous findings of the condition. The study included four patients who applied sirolimus preparation twice daily for three months, resulting in a reduction in the Facial Angiofibroma Severity Index (FASI) score. The researchers concluded that topical sirolimus is a beneficial therapy for facial angiofibromas in TSC patients. [Extracted from the article]